Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


COMPANION Results Will Better Define Resynch ICD Population – NEJM

This article was originally published in The Gray Sheet

Executive Summary

Congestive heart failure patients that are symptomatic due to ischemic cardiomyopathy and a wide QRS complex may be appropriate candidates for resynchronization therapy combined with a defibrillator, an editorial appearing in the June 13 New England Journal of Medicine suggests

You may also be interested in...

Guidant Solution To Panel Dilemma Will Not Require New Contak Implants

Guidant's Contak CD "continued access policy" IDE could augment the company's pivotal trial and allow the firm to avoid returning for a second review by the Circulatory System Devices Panel.

ASTM Developing Standard To Tackle Dried Blood On Steel Devices

ASTM International is proposing a new standard that will provide a cleaning agent formula for removing dried blood from stainless steel medical devices.

Executives On The Move: CEOs Named At Elevation Oncology, PainReform Ltd

Executive appointments at MyoKardia, Scancell Holdings and Sutro Biopharma




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts